Products

Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.

Connect With Us

All Products (882)

Quick filters: Solid Tumour Hematologic Both Name A-Z Name Z-A

Therapeutic Areas

Sort by

Molecule	Drug Class / Mechanism	Oncology Type
Pembrolizumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Pembrolizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Daratumumab	Anti-CD38 / SLAMF7 mAb	Hematologic (Multiple Myeloma)
Molecule Daratumumab Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Anti-CD38 / SLAMF7 mAb
Nivolumab	Anti-PD-1 mAb	Both (Solid & Hematologic)
Molecule Nivolumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Osimertinib	EGFR / HER2 Tyrosine Kinase Inhibitor	Solid Tumour
Molecule Osimertinib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism EGFR / HER2 Tyrosine Kinase Inhibitor
Durvalumab	Anti-PD-L1 mAb	Solid Tumour
Molecule Durvalumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Enzalutamide	Antiandrogen	Solid Tumour (Prostate)
Molecule Enzalutamide Therapeutic Category Hormonal Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Antiandrogen
Abemaciclib	CDK Inhibitor	Solid Tumour
Molecule Abemaciclib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism CDK Inhibitor
Ibrutinib	BTK Inhibitor	Hematologic (Lymphoma/CLL)
Molecule Ibrutinib Therapeutic Category Targeted Therapy Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism BTK Inhibitor
Ruxolitinib	JAK Inhibitor	Hematologic (MPN)
Molecule Ruxolitinib Therapeutic Category Targeted Therapy Oncology Type Hematologic (MPN) Drug Class / Mechanism JAK Inhibitor
Trastuzumab Deruxtecan	Anti-HER2 Agent	Solid Tumour (Breast/Gastric)
Molecule Trastuzumab Deruxtecan Therapeutic Category Targeted Therapy (Antibody / ADC) Oncology Type Solid Tumour (Breast/Gastric) Drug Class / Mechanism Anti-HER2 Agent
Ribociclib	CDK Inhibitor	Solid Tumour
Molecule Ribociclib Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism CDK Inhibitor
Atezolizumab	Anti-PD-L1 mAb	Solid Tumour
Molecule Atezolizumab Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb

Pembrolizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Daratumumab Immunotherapy (Monoclonal Antibody)
Therapeutic Category Immunotherapy (Monoclonal Antibody) Oncology Type Hematologic (Multiple Myeloma) Drug Class / Mechanism Anti-CD38 / SLAMF7 mAb
Nivolumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Both (Solid & Hematologic) Drug Class / Mechanism Anti-PD-1 mAb
Osimertinib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism EGFR / HER2 Tyrosine Kinase Inhibitor
Durvalumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb
Enzalutamide Hormonal Therapy
Therapeutic Category Hormonal Therapy Oncology Type Solid Tumour (Prostate) Drug Class / Mechanism Antiandrogen
Abemaciclib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism CDK Inhibitor
Ibrutinib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Hematologic (Lymphoma/CLL) Drug Class / Mechanism BTK Inhibitor
Ruxolitinib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Hematologic (MPN) Drug Class / Mechanism JAK Inhibitor
Trastuzumab Deruxtecan Targeted Therapy (Antibody / ADC)
Therapeutic Category Targeted Therapy (Antibody / ADC) Oncology Type Solid Tumour (Breast/Gastric) Drug Class / Mechanism Anti-HER2 Agent
Ribociclib Targeted Therapy
Therapeutic Category Targeted Therapy Oncology Type Solid Tumour Drug Class / Mechanism CDK Inhibitor
Atezolizumab Immunotherapy (Checkpoint Inhibitor)
Therapeutic Category Immunotherapy (Checkpoint Inhibitor) Oncology Type Solid Tumour Drug Class / Mechanism Anti-PD-L1 mAb

‹ 1 2 3 … 74 ›

Product Range

Company

Global Network

Products

Pembrolizumab

Daratumumab

Nivolumab

Osimertinib

Durvalumab

Enzalutamide

Abemaciclib

Ibrutinib

Ruxolitinib

Trastuzumab Deruxtecan

Ribociclib

Atezolizumab

Pembrolizumab

Daratumumab

Nivolumab

Osimertinib

Durvalumab

Enzalutamide

Abemaciclib

Ibrutinib

Ruxolitinib

Trastuzumab Deruxtecan

Ribociclib

Atezolizumab